Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Antigenics To Stimulate Immunology Projects With Stimulon From Aquila

  • News

Executive Summary

Antigenics expects to boost its infectious disease and autoimmune product development with Aquila's vaccine adjuvant Stimulon QS-21 following a proposed merger.

You may also be interested in...



Agenus Teams Up With NewVac On Russian Deal

The Massachusetts biotech has found a partner to commercialize its cancer vaccine in Russia and develop the drug for other indications.

Roche Kytril Acquisition From SmithKline Strengthens Hospital Focus In U.S.

Roche's acquisition of the anti-emetic Kytril from SmithKline Beecham will build on Roche's strength in the U.S. hospital market.

Roche Kytril Acquisition From SmithKline Strengthens Hospital Focus In U.S.

Roche's acquisition of the anti-emetic Kytril from SmithKline Beecham will build on Roche's strength in the U.S. hospital market.

Table

View full table

Tags:
Latest Headlines

BrainStorm’s NurOwn Gets Many, Many Thumbs Down From US FDA Panel

Imbruvica, Enbrel, Stelara Offer Best Chance Of Savings From Medicare Negotiation In First Round

FTC Commissioner Recusal Decisions Should Be Public, US Chamber Of Commerce Says

Preparing For A Shutdown: US FDA To Retain 81% Of Workforce, Thanks Mostly To User Fees

See All
UsernamePublicRestriction

Register

PS036536

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By